Costimulatory Molecule Development Solution

Costimulatory Molecule Development for Potent Vaccine Strategies

Costimulatory molecules are critical orchestrators of the immune system, serving as the "second signal" necessary for full T-cell activation and robust adaptive immunity. At Creative Biolabs, we provide a specialized costimulatory molecule development solution tailored for preclinical vaccine research. By engineering and validating molecules such as CD40, OX40, 4-1BB, and GITR agonists, we empower global researchers to enhance the potency, durability, and specificity of next-generation cancer and infectious disease vaccines. Our end-to-end platform bridges the gap between target selection and IND-enabling data packages.

Strategic Modulators: Costimulatory Molecules as Molecular Adjuvants

Amplifying the Immune Signal

In modern vaccine design, antigen presentation alone is often insufficient to overcome tumor immunosuppression or establish long-term memory. Costimulatory molecules act as "molecular adjuvants," providing the necessary co-signals to APCs (Antigen-Presenting Cells) and T cells. Our preclinical services focus on developing these molecules as functional modules—whether as recombinant proteins, mRNA-encoded cargos, or viral-vector payloads—to significantly boost Th1/CTL responses and immunological persistence.

Integrated Development Strategy
We don't just produce molecules; we optimize them within the context of your vaccine platform (e.g., LNP-mRNA, viral vectors, or DC vaccines) to ensure synergistic activation and a minimized systemic toxicity profile.

Core Preclinical Objectives We Deliver:
Custom design of multimeric agonists to maximize receptor clustering.
In vitro screening for APC maturation (CD80/86) and IL-12 secretion.
Optimization of co-delivery formats (e.g., Ag-Agonist Fusion vs. Co-LNP).
Systemic vs. Local immune kinetic profiling in animal models.

Costimulatory Molecules vs. Conventional Adjuvants

Parameter	Conventional Adjuvants (Alum/Oil-in-Water)	Costimulatory Molecule Modulators
Mechanism	Primarily innate activation (TLR/PRR) and depot effect.	Direct "Signal 2" engagement for T-cell/B-cell specific expansion.
Immune Outcome	Often biased toward Th2 or general inflammation.	Programmable Th1/CTL dominance and memory formation.
Specificity	Non-specific stimulation of the innate system.	Targeted modulation of specific costimulatory pathways (e.g., CD40, OX40).
Platform Adaptability	Physical mixing; stability varies with Ag types.	Seamless integration into mRNA, DNA, or viral-vector vaccines.

Comprehensive Preclinical Service Modules

Molecular Design & Expression

Building high-performance agonists with optimized bioactivity.

Target selection: TNF superfamily (CD40, 4-1BB, OX40) or Ig superfamily (ICOS).
Engineering: Fc-fusion proteins, multimeric ligands, and scFv-agonists.
Codon optimization for mRNA/DNA-based expression modules.
High-purity expression in mammalian or microbial systems for in vitro studies.

In Vitro Functional Validation

Mechanistic screening to identify the most potent candidates.

Receptor binding affinity & kinetics (SPR/BLI).
APC activation: DC/Macrophage maturation marker profiling by flow cytometry.
T-cell costimulation assays: Proliferation, cytokine release (MSD/Luminex), and cytotoxicity.
Reporter gene assays for pathway activation (NF-κB, AP-1).

Vaccine Co-delivery Optimization

Enhancing the synergy between antigens and costimulators.

Formulation screening: Alum adsorption, LNP encapsulation, or nano-emulsions.
Stability assessment: Assessing Ag-agonist interactions and release kinetics.
Loading efficiency & PDI/Zeta potential characterization for complex formulations.
Evaluation of local vs. systemic co-expression timing for mRNA vaccines.

In Vivo Efficacy & Mechanism (MOA)

Translating molecular activity into therapeutic protection.

Antigen-specific IgG/IgA titer and subclass analysis.
T-cell profiling: ELISpot (IFN-γ), ICS, and multi-parameter flow cytometry.
Tumor models: Efficacy in syngeneic, humanized, or challenge models.
TIL (Tumor Infiltrating Lymphocyte) analysis & spatial immune microenvironment profiling.

Preclinical Development Workflow: From Concept to POC

Phase 1 — Strategic Target Consulting

Selection of optimal costimulatory pathways (e.g., CD40 for DC activation, OX40 for memory maintenance) based on the specific vaccine indication and desired immune profile (cellular vs. humoral).

Phase 2 — Candidate Engineering & Synthesis

Design of 3–10 variants, including Fc-engineering for half-life extension and multimerization strategies to ensure potent receptor clustering. Synthesis of recombinant proteins or mRNA/LNP modules.

Phase 3 — High-Throughput In Vitro Lead Ranking

Rigorous screening using SPR/BLI for binding kinetics and cell-based functional assays. We evaluate APC maturation markers and T-cell cytokine "radar charts" to rank candidates by potency and safety.

Phase 4 — Synergistic POC & In Vivo Validation

Integrating the lead costimulatory module with vaccine antigens. We perform in vivo proof-of-concept studies to measure tumor regression, survival, and long-term memory durability in syngeneic models.

Phase 5 — Safety Window & CMC Support

Assessing the "safety window" by monitoring systemic cytokine release (CRS risk) and local tolerance. We provide comprehensive data packages, including analytical method validation and scale-up feasibility reports.

The Immuno-Accelerator Platform: Enabling Technologies

Clustering-Enhanced Engineering

Costimulatory receptors often require high-order clustering for signaling. We utilize proprietary scaffold technologies to create multivalent agonists that outperform standard bivalent antibodies in vitro and in vivo.

Integrated Multi-Omics Profiling

Utilizing NGS and spatial transcriptomics to map the immune landscape post-vaccination. We identify predictive biomarkers and mechanistic shifts in the tumor microenvironment (TME).

Smart Co-Delivery Systems

Advanced LNP and biomaterial platforms designed to co-encapsulate antigens and costimulators, ensuring they reach the same APC simultaneously for maximal cross-presentation and T-cell priming.

Why Choose Creative Biolabs for Costimulatory Development?

Unrivaled Pathway Expertise

Deep specialization in CD40, 4-1BB, OX40, GITR, and CD27 pathways with extensive historical data on molecule performance.

Platform-Agnostic Integration

Whether you are developing peptide, mRNA, viral-vector, or cell-based vaccines, our modules are designed for seamless synergy.

High-Resolution Analytics

Access to 30-color flow cytometry, digital pathology scanning, and Luminex multiplexing for comprehensive immune characterization.

IND-Enabling Reliability

Rigorous preclinical QC and traceability ensure that your data packages meet international standards for translation into the next phase.

Research Insight: The CD70-CD27 Axis as a Prognostic Target in SCLC

Harnessing Costimulation in Aggressive Tumors

Recent research published in Cancer Immunology, Immunotherapy (2025) has elucidated the critical role of the CD70-CD27 costimulatory axis in Small Cell Lung Cancer (SCLC). While CD70/CD27 signaling traditionally promotes T-cell activation, its dysregulation in the SCLC microenvironment serves as a potent prognostic indicator and a target for therapeutic modulation.

Prognostic Impact of CD70: High CD70 expression (found in 46% of SCLC tumors) is significantly correlated with decreased overall survival (HR: 1.795), particularly within tumor nests and CD68+ macrophages.
TME Compartmentalization: CD27 expression is primarily restricted to the stroma, where high density is linked to reduced CD8+ T-cell infiltration, suggesting a potential role in immune exclusion.
Targeting Opportunity: In in vitro models, targeting the CD70-CD27 axis via engineered agonists or vaccine modules can re-sensitize immune-desert tumors, establishing SCLC as a prime candidate for costimulatory-enhanced vaccine strategies.

Clinical and immune responses to personalized Neo-DCVac therapy in patient 1 with metastatic lung adenocarcinoma.

Fig.1 Clinical and immune responses of personalized Neo-DCVac in metastatic lung adenocarcinoma patient 1.^1.2

FAQs Regarding Costimulatory Development Services

Pathways like OX40 and 4-1BB are highly effective for memory maintenance. OX40 primarily promotes the survival and expansion of CD4+ and CD8+ effector T cells, while 4-1BB is a potent driver of CD8+ T-cell persistence. Our in vitro assays can help you select the best target for your specific vaccine antigen.

We utilize "safety-by-design" strategies, including local co-delivery (e.g., intratumoral injection or localized mRNA expression) and Fc-engineering to tune the agonist's threshold for activation. In vitro cytokine storm assays using human PBMCs are performed to establish a preclinical safety window.

Yes. We specialize in designing Ag-Agonist fusion proteins. This ensures that the costimulatory signal is delivered precisely at the moment of antigen recognition by the T-cell or APC, significantly increasing the efficiency of the immune response while reducing off-target effects.

We primarily use Surface Plasmon Resonance (SPR) and Bio-Layer Interferometry (BLI) to measure real-time binding kinetics ($K_D$, $k_{on}$, $k_{off}$). These high-resolution tools are essential for confirming that engineered multimeric agonists maintain the correct binding stoichiometry.

Absolutely. We offer specialized mRNA engineering and LNP co-formulation services. We can optimize the co-expression of the costimulatory molecule alongside your antigen, ensuring potent in vivo expression and synergistic immune activation.